RT Journal Article
SR Electronic
T1 Compound heterozygous mutations in the kinase domain of IKKα lead to immunodeficiency and immune dysregulation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.17.24307356
DO 10.1101/2024.05.17.24307356
A1 Riller, Quentin
A1 Sorin, Boris
A1 Courteille, Charline
A1 Ho-Nhat, Duong
A1 Voyer, Tom Le
A1 Debray, Jean-Christophe
A1 Stolzenberg, Marie-Claude
A1 Pellé, Olivier
A1 Becquard, Thomas
A1 Riestra, María Rodrigo
A1 Berteloot, Laureline
A1 Migaud, Mélanie
A1 Delage, Laure
A1 Jeanpierre, Marie
A1 Boussard, Charlotte
A1 Brunaud, Camille
A1 Magérus, Aude
A1 Michel, Victor
A1 Roux, Camille
A1 Picard, Capucine
A1 Masson, Cécile
A1 Bole-Feysot, Christine
A1 Cagnard, Nicolas
A1 Corneau, Aurélien
A1 Meyts, Isabelle
A1 Baud, Véronique
A1 Casanova, Jean-Laurent
A1 Fischer, Alain
A1 Dejardin, Emmanuel
A1 Puel, Anne
A1 Boulanger, Cécile
A1 Neven, Bénédicte
A1 Rieux-Laucat, Frédéric
YR 2024
UL http://medrxiv.org/content/early/2024/05/17/2024.05.17.24307356.abstract
AB IKKα, encoded by CHUK, is crucial in the non-canonical NF-κB pathway and part of the IKK complex activating the canonical pathway alongside IKKβ. Absence of IKKα cause fetal encasement syndrome in human, fatal in utero, while an impaired IKKα-NIK interaction was reported in a single patient and cause combined immunodeficiency. Here, we describe compound heterozygous variants in the kinase domain of IKKα in a female patient with hypogammaglobulinemia, recurrent lung infections, and Hay-Wells syndrome-like features. We showed that both variants were loss-of-function. Non-canonical NF-κB activation was profoundly diminished in stromal and immune cells while the canonical pathway was partially impaired. Reintroducing wild-type CHUK restored non-canonical NF-κB activation. The patient had neutralizing autoantibodies against type I IFN, akin to non-canonical NF-κB pathway deficiencies. Thus, this is the first case of bi-allelic CHUK mutations disrupting IKKα kinase function, broadening non-canonical NF-κB defect understanding and suggesting IKKα’s role in canonical NF-κB target gene expression in human.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe would like to thank the core facilities of the Imagine Institute (bioinformatics, genomics, flow cytometry) and the Flow Cytometry Platform of the Pitie-Salpetriere Hospital (CyPS) for CyTOF acquisition and technical advice. This work was supported by the Institut National de la Sante et de la Recherche Medicale (INSERM) and by government grants managed by the Agence National de la Recherche as part of the Investment for the Future program (Institut Hospitalo-Universitaire Imagine, grant no. ANR-10-IAHU-01; Recherche Hospitalo-Universitaire, grant no. ANR-18-RHUS-0010), the Centre de Reference Deficits Immunitaires Hereditaires (CEREDIH), the Agence National de la Recherche (grant nos. ANR-18-CE17-0001 Action; and ANR-22-CE15-0047-02 BREAK-ITP), the Fondation pour la recherche Medicale (FRM: EQU202103012670). The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St Giles Foundation, the National Institutes of Health (NIH) (R01AI127564), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JBP Foundation, the French National Research Agency (ANR), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), ANR GENVIR (ANR-20-CE93-003), ANR AAILC (ANR-21-LIBA-0002) and ANR AI2D (ANR-22-CE15-0046) projects, the ANR-RHU programme (ANR-21-RHUS-08-COVIFERON), the HORIZON-HLTH-2021-DISEASE-04 programme under grant agreement 101057100 (UNDINE), the Square Foundation, Grandir-Fonds de solidarite pour l’enfance, the SCOR Corporate Foundation for Science, the Battersea & Bowery Advisory Group, Stavros Niarchos Foundation (SNF) as part of its grant to the SNF Institute for Global Infectious Disease Research at The Rockefeller University, William E. Ford, General Atlantic’s Chairman and Chief Executive Officer, Gabriel Caillaux, General Atlantic’s Co-President, Managing Director and Head of business in EMEA, and the General Atlantic Foundation, the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Sante et de la Recherche Medicale (INSERM) and of Paris Cite University. Tom Le Voyer (TLV) was supported by the Bettencourt-Schueller Foundation and the MD-PhD program of Imagine Institute. This work was also supported by grants from Institut National du Cancer, Fondation ARC pour la Recherche sur le Cancer, University Paris Cite, 12 Rounds contre le Cancer (V.B.), and Doctoral funding from the French Ministry of Higher Education and Research (T.B.). I.M. is a senior clinical investigator at FWO Vlaanderen and is supported by the Jeffrey Modell Foundation and by FWO Grant G0B5120N. This work is supported by ERN-RITA. QR received an Institut Imagine MD-PhD fellowship and a Societe Nationale Francaise de Medecine Interne (SNFMI) fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the “Comite d’ethique de la recherche Assistance Publique Hopitaux de Paris” (Institutional Review Bord Number #00011928, Paris, France). The study was performed in accordance with the 1975 Declaration of Helsinki and subsequent revisions. The biological samples are part of Inserm and Imagine institute collection declared to the French Ministere de la recherche (Access to the Human Body Element Conservation Management Application no. DC-2020-3994, Paris, France).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors